GP 531
GP 531 Basic information
- Product Name:
- GP 531
- Synonyms:
-
- GP 531
- 1H-Imidazole-4-carboxamide, 5-amino-1-[5-deoxy-5-[(phenylmethyl)amino]-β-D-ribofuranosyl]-
- GP531,GP-531
- CAS:
- 142344-87-4
- MF:
- C16H21N5O4
- MW:
- 347.37
- Mol File:
- 142344-87-4.mol
GP 531 Chemical Properties
- Boiling point:
- 703.1±60.0 °C(Predicted)
- Density
- 1.60±0.1 g/cm3(Predicted)
- storage temp.
- Store at -20°C
- solubility
- DMSO: 125 mg/mL (359.85 mM)
- form
- Solid
- pka
- 13.30±0.70(Predicted)
- color
- Off-white to light yellow
GP 531 Usage And Synthesis
Uses
GP531 is a potent, second-generation adenosine regulating agent, is pharmacologically silent under basal conditions but increases localized endogenous adenosine during ischemia.
in vivo
Low-dose GP531 reduces infarct size by 34% compared with vehicle and reduces the extent of the anatomic no-reflow zone by 31% compared with vehicle. Infarct size and zone of no-reflow in the high dose are reduced by 22% and 16%, respectively. GP531 does not affect hemodynamics or blood flow. GP531 is effective at the lower dose in reducing the severity of ischemic/reperfusion injury, without inducing the adverse hemodynamic effects associated with adenosine administration such as bradycardia and hypotension[1]. GP531 infusion has no effect on heart rate or mean aortic pressure but significantly decreases left ventricular end-diastolic pressure, end-diastolic volume, end-systolic volume and end-diastolic wall stress. GP531 significantly increases left ventricular EF, deceleration time of early mitral inflow velocity and the slope of end-systolic PVR without increasing MVO2[2].
References
[1] Hale SL, et al. Cardioprotection with adenosine-regulating agent, GP531: effects on no-reflow, infarct size, and blood flow following ischemia/ reperfusion in the rabbit. J Cardiovasc Pharmacol Ther. 2010 Mar;15(1):60-7. DOI:10.1177/1074248409357742
[2] Wang M, et al. Acute intravenous infusion of an adenosine regulating agent improves left ventricular function in dogs with advanced heart failure. Cardiovasc Drugs Ther. 2013 Dec;27(6):489-98. DOI:10.1007/s10557-013-6482-9
GP 531Supplier
- Tel
- 021-58955995
- sales@medchemexpress.cn
- Tel
- +1-781-999-5354; +17819995354
- marketing@targetmol.com
- Tel
- 18818260767
- sales@chemegen.com
- Tel
- 13348960310
- 3003867561@qq.com
- Tel
- 010-60605840 15801484223;
- psaitong@jm-bio.com